Pre-treatment Monocytosis in Pediatric H3K27M-Mutant Gliomas
Neuro-Oncology Pediatrics · 24.07.2026
DOI: 10.1093/neuped/wuag043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Pediatrics, online erschienen am 24.07.2026. Verfasst von Hannah Weiss und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Systemic immune dysregulation is well-characterized in adult high-grade gliomas but remains underexplored in pediatric population. Among these, H3K27M-mutant diffuse midline gliomas are biologically and clinically distinct, with limited therapeutic options and poor prognosis. While prior studies in medulloblastoma suggest tumor-induced lymphopenia at diagnosis, the immune profile of H3K27M gliomas has not been systematically evaluated.
Methods
We performed a multicenter retrospective analysis of pretreatment complete blood counts (CBCs) in pediatric patients (≤18 years) with H3K27M-mutant gliomas (n = 37), comparing them to a control cohort with pilocytic astrocytoma (n = 61). Absolute neutrophil count (ANC), monocyte count (AMC), lymphocyte count (ALC), neutrophil-to-lymphocyte count ratio (NLCR), and monocyte-to-lymphocyte ratio (MLR) were evaluated. Patients receiving corticosteroids prior to CBC collection were excluded.
Results
No significant differences were observed in ANC, ALC, or NLCR between groups. However, the H3K27M group demonstrated significantly elevated AMC (0.70 vs. 0.50 K/μL; p = 0.012) and MLR (0.20 vs. 0.19; p = 0.021) compared to controls. Monocytosis, defined by AMC above age-adjusted means, was present in 78.4% of H3K27M patients versus 46.7% of controls (OR = 4.14, p = 0.003). These findings suggest a distinct pre-treatment immune signature in H3K27M gliomas.
Conclusions
This is the first study to identify pre-treatment monocytosis and elevated MLR in pediatric H3K27M-mutant gliomas, highlighting a novel systemic immune phenotype with potential implications for biomarker discovery and immunotherapeutic targeting. These results underscore the need for further mechanistic studies and prospective validation in larger, mutation-stratified cohorts.
Zitieren
APA
Weiss, H., Grin, E. A., Alshammari, A., Serrano, J., Fang, C., Das, A., Hawkins, C., Clymer, J., Segal, D., Karajannis, M. A., Harter, D., Hidalgo, E. T., & Snuderl, M. (2026). Pre-treatment Monocytosis in Pediatric H3K27M-Mutant Gliomas. Neuro-Oncology Pediatrics. https://doi.org/10.1093/neuped/wuag043
Vancouver
Weiss H, Grin EA, Alshammari A, Serrano J, Fang C, Das A, et al. Pre-treatment Monocytosis in Pediatric H3K27M-Mutant Gliomas. Neuro-Oncology Pediatrics. 2026. doi:10.1093/neuped/wuag043
BibTeX
@article{Weiss2026,
author = {Weiss, Hannah and Grin, Eric A and Alshammari, Anfal and Serrano, Jonathan and Fang, Camila and Das, Anirban and Hawkins, Cynthia and Clymer, Jessica and Segal, Devorah and Karajannis, Matthias A and Harter, David and Hidalgo, Eveline Teresa and Snuderl, Matija},
title = {Pre-treatment Monocytosis in Pediatric H3K27M-Mutant Gliomas},
journal = {Neuro-Oncology Pediatrics},
year = {2026},
doi = {10.1093/neuped/wuag043}
}
EUVIMED